OPTN OptiNose

Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal

Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal

YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2020 in the medium-sized company category for the third year in a row.

“We are extremely proud of the culture we have built at Optinose over the last ten years. Even during these extraordinary times, maintaining a fun and productive work environment in which people can come together and accomplish great things continues to be our highest priority,” said Peter Miller, CEO of Optinose. “We are excited to be recognized once again as a ‘Best Place to Work’ by the Philadelphia Business Journal. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives.”

“Public recognition of Optinose as a ‘Best Place to Work’ is an honor for all of us, and is only possible because of the collective commitment and contributions of our team,” added Ramy Mahmoud, MD, President and Chief Operating Officer of Optinose. “It is especially heartening that even during this uniquely fraught time in history, nearly 84% of our colleagues chose to participate in this year’s survey. We truly value colleague feedback and make concrete action plans based on the feedback from this survey. Employee engagement is a top priority: it starts with our hiring process and permeates everything we do thereafter. Nurturing a team of high-achieving professionals who are passionately motivated to improve human health, and who share clearly articulated core values, is essential to our success in developing and commercializing innovative new products.”

Optinose has grown tremendously over the past several years, and currently has more than 200 colleagues, with nearly 80 based in the headquarters in Yardley. The Company has achieved key objectives in support of the launch of its lead product XHANCE® and the conduct of multiple clinical trials. More information about the shared purpose that unites the people of Optinose is here, and more information about career opportunities is here.

The Philadelphia Business Journal names companies to its “Best Places to Work” list using a rigorous scientific process based on responses to an independent employee engagement survey conducted by Quantum Workplace. As part of the survey, employees rate the company in areas including communication and resources, individual needs, manager effectiveness, personal engagement, team dynamics, and trust in leadership.

About Optinose

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit  or follow us on and .

Optinose Investor Contact

Jonathan Neely

267.521.0531

EN
19/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptiNose

 PRESS RELEASE

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results a...

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended Dece...

 PRESS RELEASE

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceut...

 PRESS RELEASE

Optinose Announces Reporting Date for Fourth Quarter and Full Year 202...

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company’s leadership team w...

 PRESS RELEASE

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Ne...

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth quarter n...

 PRESS RELEASE

Optinose Announces 1-for-15 Reverse Stock Split

Optinose Announces 1-for-15 Reverse Stock Split YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch